Management of Hyperkalemia in Patients Taking Digoxin

Assessment and Management

• The American Heart Association recommends administering digoxin-specific Fab antibody fragments if there are signs of severe toxicity or if hyperkalemia is severe (>6.0 mmol/L) 1, 2, 3
• Clinical features suggesting digoxin toxicity include cardiac manifestations, such as enhanced atrial, junctional, or ventricular automaticity with ectopic beats or tachycardia, often combined with AV block 1, 4
• The American College of Cardiology suggests that for hyperkalemia >5.5 mmol/L with signs of digoxin toxicity, digoxin-specific Fab antibody fragments should be administered as first-line therapy 1, 5, 6
• For severe hyperkalemia (>6.0 mmol/L) with life-threatening arrhythmias, immediate administration of digoxin-specific Fab antibody is essential 1, 5

Special Considerations

• Magnesium administration is reasonable for patients with ventricular arrhythmias 1, 5
• Temporary cardiac pacing may be needed for severe bradyarrhythmias or heart block 1, 5

Monitoring and Follow-up

• Monitor serum potassium levels closely during treatment 7
• The European Society of Cardiology notes that digoxin concentration monitoring becomes unreliable after antidigoxin antibody administration 5, 6
• Monitor for side effects of digoxin-Fab, including worsening of underlying disease and hypokalemia 5
• The American College of Cardiology recommends that dialysis is not used for removal of digoxin in patients with bradycardia associated with digoxin toxicity 8, 6

Prevention of Recurrence

• When reinitiating digoxin therapy after toxicity resolves, use lower doses (0.125 mg daily or every other day) for patients with risk factors 4
• Avoid loading doses to minimize risk of toxicity 4
• Avoid concomitant medications that increase digoxin levels (amiodarone, clarithromycin, verapamil, etc.) 4